Background: Psoriasis prevalence and characteristics in Asia, Central Europe, and Latin America have not been thoroughly investigated and there are no large trials for biologic treatments for patients from these regions. The goal of this analysis was to report clinical response to anti-tumor necrosis factor-alpha treatment in these patients.
Background
Psoriasis is a chronic inflammatory skin condition characterized by exacerbations and remissions and estimated to affect approximately 125 million people (2-3 %) worldwide [1] . In the United States, where such data are available, the prevalence of psoriasis varies among ethnicity, with 0.47 % of Chinese [2] , 1.3 % of African Americans and 1.6 % of Hispanic affected compared with 3.6 % of Caucasians [1] . As such, it is possible that patients from different parts of the world may respond differently to treatment.
The goal of treatment in psoriasis is to alleviate symptoms as rapidly as possible and maintain the response over time. Current treatment guidelines in both the United States and Europe support the combination of topical and systemic therapies, including biologic agents, in order to achieve these goals [3] [4] [5] [6] . Although the effectiveness of biologic agents is well-established through clinical trials in the United States and Europe [5] [6] [7] , these agents have not been studied extensively in many parts of the world.
The PRISTINE trial was a multinational, randomized, double-blind study in patients with moderate-to-severe plaque psoriasis in which investigators evaluated the efficacy and safety of two dosing regimens of etanercept [8] . This trial included patients from Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand. The objective of the subset analysis reported here was to evaluate the efficacy of etanercept therapy in patients from countries in Asia, Central Europe, and Latin America.
Methods

Study details
The details of the PRISTINE trial have been previously published [8] . Briefly, patients ≥18 years of age with stable moderate-to-severe plaque psoriasis were randomized to receive 50 mg etanercept subcutaneously either once weekly (QW) or twice weekly (BIW) for 12 weeks, after which all patients received open-label, 50 mg etanercept subcutaneously QW for an additional 12 weeks, i.e. QW/QW or QW/BIW dosing groups (Fig. 1 ). Concomitant methotrexate was allowed (≤20 mg/week) if doses were stable from at least 28 days prior to baseline through the end of study. Only mild topical corticosteroids were permitted on scalp, axillae and groin for first 12 weeks; topical medications (corticosteroids of all potencies, vitamin D analogues and combination products) were allowed as needed, at physician's discretion, during the second 12 weeks, consistent with therapeutic practice. Of the 273 patients enrolled in the PRISTINE trial, 171 patients were eligible for this subset analysis.
The study protocol was reviewed and approved by an independent Ethics Committee prior to initiation. The study was conducted in compliance with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. The PRISTINE trial is registered on ClinicalTrials.gov, identifier NCT00663052.
Study endpoints
Primary efficacy was measured as the proportion of patients achieving 50 %, 75 %, or 90 % improvement in Psoriasais Area and Severity Index (PASI), PASI 50, PASI 75, and PASI 90, respectively, at weeks 8, 12, and 24. Other efficacy endpoints included the percentage of patients who achieved a status of "clear" or "almost clear" on the Physician's Global Assessment (PGA) of psoriasis, time to achieving PGA first "clear" or "almost clear" status, and percentage reduction in affected body surface area (BSA). Health-related quality of life (HRQoL) measures included Dermatology Life Quality Index (DLQI) [9] , EuroQoL-5 Dimension (EQ-5D™) [10, 11] , Work Productivity and Activity Impairment scale (WPAI) [12] and Functional Activity in Chronic Therapy (FACIT) [13] .
Statistical analyses
For continuous efficacy parameters, treatment groups were compared in 1-way analysis of variance for baseline parameters or in analysis of covariance models of week 12/24 change from baseline parameters with treatment group as a factor and baseline measurement as a covariate. For dichotomous or categorical parameters, Fisher's exact test was used. The last observation was carried forward for patients for whom data were not available at any time point. 
Results
Patients
Of the 273 patients enrolled in the PRISTINE trial, all 171 patients from Asia (Taiwan, n = 25; Thailand, n = 22), Central Europe (Czech Republic, n = 12; Hungary, n = 50), and Latin America (Argentina, n = 28; Mexico, n = 34) were included in the analysis. Since the number of patients from each region was small, they were pooled together for this subset analysis (Fig. 2) . The baseline demographics were similar between the etanercept 50 mg QW/QW and BIW/QW treatment groups (Table 1 ). In addition, the history of psoriasis, the extent of the disease, the presence and duration of psoriatic arthritis, and baseline HRQoL measures were also similar between the two groups of patients (Table 1) . The baseline characteristics of the patients in this subset were comparable to those from the overall PRISTINE population ( Table 2) .
Efficacy analyses
There were more patients achieving PASI 50, PASI 75, and PASI 90 in the group that received etanercept 50 mg BIW than in the group that received etanercept 50 mg QW over the time course of the study (Fig. 3 ). Statistically significant difference between the two treatment groups was evident as early as week 4 in PASI 50. Statistically significant difference in PASI 75 was observed by week 8 and in PASI 90 by week 12 (Fig. 3) . After 12 weeks of treatment, i.e. at the end of the (Table 3) . Improvements from baseline were also observed in PGA and BSA scores (p < 0.0001) at weeks 12 and 24 in both treatment groups (Fig. 4) Table 4 .
HRQoL analyses
Statistically significant (p < 0.001) improvements from baseline in all measures of HRQoL were observed in both treatment groups by week 12 and were maintained to week 24 (Table 5 ). In addition, the difference in the observed improvement in DLQI and EQ-5D scores at week 12 between the two treatment groups was statistically significant (p < 0.05).
Safety analyses
Individual safety analysis by country or region was not performed since the trial was designed to randomize all enrolled patients and not stratified by geographic location. The complete safety data for the PRISTINE trial have been reported before [8] . 
Discussion
Guidelines for the treatment of psoriasis have been well established in the United States and Western Europe [3] [4] [5] [6] and, more recently, in the Czech Republic [14] and Mexico [15] . These same treatment paradigms have In this post-hoc, subset analysis, we examine the responses of patients from six countries (Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand) in three regions of the world (Asia, Central Europe, and Latin America) in which there are no current guidelines for the treatment of psoriasis other than in the Czech Republic [14] and Mexico [15] . Of the 273 patients originally enrolled in the PRISTINE trial, 171 patients were from these three regions. However, since the number of patients from each of the six countries was small, they were pooled for descriptive statistical analyses.
The percentages of patients achieving PASI 50, PASI 75 or PASI 90 in response to etanercept treatment were numerically greater in this subset than the corresponding percentages in the overall PRISTINE population [8] at both the 12-and 24-week time points. Similarly, the percentage of patients achieving a PGA status of clear or almost clear in response to etanercept treatment was also numerically greater in this subset than in the overall PRISTINE study population. Even though some outcomes appear to have slightly better responses numerically for this subpopulation compared with the overall study population [8] , the underlying cause for these differences is unclear. This could be related to shorter psoriatic arthritis disease duration; slightly higher disease severity, e.g. BSA and PASI, at baseline for this subpopulation, allowing for greater improvement; slightly higher body mass index and smaller waist-to-hip ratio among the females in this subpopulation; slightly fewer Caucasians; slightly higher number of patients with secondary diagnosis of psoriatic arthritis, diabetes or hypertension; or random chance. Since the study was designed to randomize all enrolled patients without stratification by their geographic location, the patients from these six countries were not homogenously distributed between the two treatment groups. Thus, any analysis comparing the responses of the subpopulation from these six Missing data were imputed using the last observation carried forward method *p < 0.05 between treatment groups at the same time point. † p < 0.01 from baseline within treatment group BIW twice weekly, DLQI Dermatology Life Quality Index, EQ-5D EuroQoL 5 Dimension, FACIT Functional Activity in Chronic Therapy, HRQoL health-related quality of life, QW once weekly, SEM standard error of the mean, WPAI Work Productivity and Activity Impairment scale countries with those from the rest of the enrolled patients could introduce bias in the results which could be random or due to regional differences, e.g., accepted standard of care. The Kaplan-Meier estimates for time to first response also demonstrate the rapidity with which patients in this subset experienced the benefits of etanercept treatment. As might be expected, the response time was shorter for those receiving etanercept BIW (median time 85 days, 95 % CI: 59-86 days) compared with those receiving etanercept QW during the first 12 weeks of the study (median time 113 days, 95 % CI: 85-141 days). This difference was statistically significant based on nonoverlapping 95 % CIs suggesting faster and greater benefit to patients from the BIW dosing regimen than QW dosing regimen.
Analysis of HRQoL measures demonstrated statistically significant (p < 0.01) improvement of scores from baseline in response to etanercept treatment for all parameters in both treatment groups at both 12 weeks and 24 weeks. Furthermore, the differences in the improvements observed for DLQI and EQ-5D scores at week 12 between the BIW and QW treatment groups were statistically significant (p < 0.05). These data parallel the data observed for the efficacy analyses for this subset of patients.
